Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clozapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.98 |
| ▸ | DRD4 | P21917 | 7/20 | 0.98 |
| ▸ | DRD1 | P21728 | 4/20 | 0.98 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.98 |
| ▸ | DRD3 | P35462 | 3/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clozapine SCHEMBL29180214 | 1.00 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL20876213 | 0.99 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29360001 | 0.99 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL5501558 | 0.99 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29433929 | 0.99 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL8397 | 0.99 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29590817 | 0.99 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29041024 | 0.98 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL28648626 | 0.98 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL28700741 | 0.98 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2010048264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090075951-A1 | Methods and Reagents for the Treatment of Inflammatory Disorders | COMBINATORX, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090005358-A1 | Compositions and methods for treating medical conditions | LG CHEM, LTD. (KR) | 2009-01-01 | — | — | US | disclosed |
| WO-2009002507-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1599212-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INCORPORATED | 2005-09-01 | — | — | US | disclosed |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | COMBINATORX, INCORPORATED | 2005-08-25 | — | — | US | disclosed |
| WO-2005048927-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| US-4310524-A | TCA Composition and method for rapid onset antidepressant therapy | RICHARDSON-MERRELL, INC. (US) | 1982-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005358-A1 | Compositions and methods for treating medical conditions | ITCH, TSLP, P2RX5 | DRD2 4247/4885HTR2A 651/4885CHRM1 3012/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | DRD2 59/4885HTR2A 10/4885CHRM1 1417/4885 |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | IL5, TNF, LTC4S | DRD2 3820/4885HTR2A 2350/4885CHRM1 3454/4885 |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, CMA1, CCL11 | DRD2 2151/4885HTR2A 842/4885CHRM1 1439/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | DRD2 3053/4885HTR2A 2023/4885CHRM1 3915/4885 |
| US-20090075951-A1 | Methods and Reagents for the Treatment of Inflammatory Disorders | IL5, TNF, LTC4S | DRD2 3820/4885HTR2A 2350/4885CHRM1 3454/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | DRD2 4506/4885HTR2A 3559/4885CHRM1 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.